CBI’s Immuno-Oncology Breakthrough Summit provides pharmaceutical and biotech companies the knowledge and resources necessary to successfully bring immuno-oncology products from a clinical to commercial stage. This conference addresses key challenges faced throughout the drug life cycle and provides updates from regulatory bodies and economic perspectives to navigate this rapidly evolving landscape.

KEY BENEFITS OF ATTENDING INCLUDE:

• Assess the state of the industry by discussing abstracts and considering strategies implemented by successful organizations
• Build and manage partnerships from R&D through commercial stages of the immunotherapy life cycle
• Bridge the gap between clinical development and commercialization planning from Phase II to Phase III
• Discover best practices when designing clinical trials to obtain approvals and reimbursement
• Discuss challenges of combination therapies and their complexities
• Justify price of product to maximize market access
• Develop a unique product identity to differentiate and demonstrate key benefits in order to gain coverage by payers
• Gain strategies to overcome major challenges to achieve market access